Rituximab Treatment in a Patient with Active Graves' Orbitopathy and Psoriasis
TURK OFTALMOLOJI DERGISI-TURKISH JOURNAL OF OPHTHALMOLOGY, cilt.47, sa.1, ss.42-46, 2017 (ESCI, Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 47 Sayı: 1
- Basım Tarihi: 2017
- Doi Numarası: 10.4274/tjo.26780
- Dergi Adı: TURK OFTALMOLOJI DERGISI-TURKISH JOURNAL OF OPHTHALMOLOGY
- Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.42-46
- Anahtar Kelimeler: Graves' orbitopathy, rituximab, psoriasis, MONOCLONAL-ANTIBODY RITUXIMAB, B-CELL DEPLETION, TARGETED THERAPY, DISEASE, OPHTHALMOPATHY, PATHOGENESIS, MECHANISMS
- Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
- Eskişehir Osmangazi Üniversitesi Adresli: Evet
Özet
Management of Graves' orbitopathy remains an important therapeutic challenge. Current therapeutic modalities are unsatisfactory in about one third of patients. Rituximab is a monoclonal antibody against CD20 antigen that is expressed in mature and immature B cells. Early experience with rituximab suggests that it is a promising alternative therapy for Graves' orbitopathy. Here we report a case of a 49-year-old woman with Graves' orbitopathy and psoriasis. The patient received 2 infusions of 1 g rituximab 2 weeks apart. Although there was improvement in inflammatory signs of the disease, proptosis did not change after the treatment.